Slagle Financial LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Slagle Financial LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 91.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,336 shares of the biopharmaceutical company's stock after selling 25,788 shares during the period. Slagle Financial LLC's holdings in Gilead Sciences were worth $262,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $339,000. Personal CFO Solutions LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $207,000. Johnson Investment Counsel Inc. increased its holdings in shares of Gilead Sciences by 10.3% in the fourth quarter. Johnson Investment Counsel Inc. now owns 16,629 shares of the biopharmaceutical company's stock worth $1,536,000 after buying an additional 1,549 shares during the period. Finally, Independent Advisor Alliance grew its stake in shares of Gilead Sciences by 35.4% in the fourth quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock worth $2,968,000 after purchasing an additional 8,398 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.99 during midday trading on Thursday, hitting $114.23. The company had a trading volume of 2,410,898 shares, compared to its average volume of 8,763,631. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The company has a market cap of $142.09 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $68.14 and a 12-month high of $119.96. The company has a fifty day moving average of $107.40 and a two-hundred day moving average of $104.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.32) EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.77%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the transaction, the chief financial officer owned 165,110 shares of the company's stock, valued at $18,190,168.70. This represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider owned 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock valued at $6,340,745 in the last 90 days. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Morgan Stanley boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.